Skip to main content

Table 1 Correlations between clinicopathological parameters and STAS in ADC

From: Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system

Parameters In total STAS p
Positive(n(%)) Negative(n(%))
In total 303 183(60.4) 120(39.6)  
Gender
 Female 153 91(49.7) 62(51.7) 0.741
 Male 150 92(50.3) 58(48.3)
Age
  ≤ 65 157 91(49.7) 66(55.0) 0.369
  > 65 146 92(50.3) 54(45.0)
Smoking history
 Non-smoker 183 112(61.2) 71(59.2) 0.723
 Smoker 120 71(38.8) 49(40.8)
Tumor size
  ≤ 3 cm 177 94(51.4) 83(69.2) 0.002
  > 3 cm 126 89(48.6) 37(30.8)
Predominant subtype
 Acinar 154 89(48.6) 65(54.2) 0.104
 Papillary 82 54(29.5) 28(23.3)
 Lepidic 45 27(14.8) 18(15.0)
 Solid 6 1(0.5) 5(4.2)
 Micropapillary 16 12(6.6) 4(3.3)
Presence of micropapillary
 Absent 229 115(62.8) 114(95.0) < 0.001
 Present 74 68(37.2) 6(5.0)
Pleural invasion
 Absent 168 93(50.8) 75(62.5) 0.045
 Present 135 90(49.2) 45(37.5)
Vascular invasion
 Absent 189 92(50.3) 97(80.8) < 0.001
 Present 114 91(49.7) 23(19.2)
Lymphatic invasion
 Absent 148 58(31.7) 90(75.0) < 0.001
 Present 155 125(68.3) 30(25.0)
Perineural invasion
 Absent 280 163(89.1) 117(97.5) 0.007
 Present 23 20(10.9) 3(2.5)
Tumor necrosis
 Absent 196 103(56.3) 93(77.5) < 0.001
 Present 107 80(43.7) 27(22.5)
Tumor relapse
 Absent 212 110(60.1) 102(85.0) < 0.001
 Present 91 73(39.9) 18(15.0)
Pathological stage
 Stage I-II 230 128(69.9) 102(85.0) 0.003*
 StageIA 86 39(21.3) 47(39.2) 0.111
 StageIB 87 50(27.3) 37(30.8)
 StageIIA 46 29(15.8) 17(14.2) 0.146
 StageIIB 11 10(5.5) 1(0.8)
 Stage III-IV 73 55(30.1) 18(15.0)  
EGFR mutation
 Negative 143 96(52.5) 47(39.2) 0.023
 Positive 160 87(47.5) 73(60.8)
KRAS mutation
 Negative 243 148(91.9) 95(96.0) 0.201
 Positive 17 13(8.1) 4(4.0)
ALK rearrangement
 Negative 279 160(87.4) 119(99.2) < 0.001
 Positive 24 23(12.6) 1(0.8)
ROS1 rearrangement
 Negative 294 174(95.1) 120(100.0) 0.013
 Positive 9 9(4.9) 0(0)
  1. *Correlation between stage I-II and stage III-IV
\